MX2017008939A - Forma de dosificacion que incluye una solucion solida de drogas amorfas. - Google Patents

Forma de dosificacion que incluye una solucion solida de drogas amorfas.

Info

Publication number
MX2017008939A
MX2017008939A MX2017008939A MX2017008939A MX2017008939A MX 2017008939 A MX2017008939 A MX 2017008939A MX 2017008939 A MX2017008939 A MX 2017008939A MX 2017008939 A MX2017008939 A MX 2017008939A MX 2017008939 A MX2017008939 A MX 2017008939A
Authority
MX
Mexico
Prior art keywords
solid solution
kto
hme
kollidon
single phase
Prior art date
Application number
MX2017008939A
Other languages
English (en)
Inventor
Del Pilar Noriega Escobar Maria
Restrepo Uribe Laura
Mejia Marco Enrique Sanjuan
Arturo Altamar Carlos
Andrea Silva Blanco Claudia
Original Assignee
Procaps S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56285892&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017008939(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Procaps S A filed Critical Procaps S A
Publication of MX2017008939A publication Critical patent/MX2017008939A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Indole Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

La disolución de Ingredientes Farmacéuticos Activos en fundidos poliméricos juega un papel importante en la fabricación de fármacos que utilizan polímeros como excipientes. La cinética de disolución es esencial para diseñar el equipo de procesamiento, describir las condiciones operativas y definir las propiedades del material, por ejemplo, el par polímero-API adecuado. En una realización de la invención, la solubilidad del Ketoprofeno (KTO) en Soluplus(r), Kollidon(r) VA64, Kollidon(r) SR y una combinación de tres; Se analizó en condiciones de procesamiento por extrusión en caliente (HME). Las técnicas de caracterización térmica muestran que una solución sólida amorfa monofásica (sólo una Tg) fue alcanzada por HME a 120 ° C y 70 rpm. La estabilidad de la muestra se analizó durante 4 semanas y la solución sólida amorfa monofásica se mantuvo durante ese tiempo. Se logró un perfil de liberación prolongado de ketoprofeno (KTO), liberando el 100% de ketoprofeno (KTO) en 12 h. La invención es particularmente útil para dirigir un perfil de liberación específico.
MX2017008939A 2015-01-06 2015-09-10 Forma de dosificacion que incluye una solucion solida de drogas amorfas. MX2017008939A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562100117P 2015-01-06 2015-01-06
US14/849,571 US20160193151A1 (en) 2015-01-06 2015-09-09 Dosage form incorporating an amorphous drug solid solution
PCT/US2015/049412 WO2016111725A1 (en) 2015-01-06 2015-09-10 Dosage form incorporating an amorphous dgug solid solution

Publications (1)

Publication Number Publication Date
MX2017008939A true MX2017008939A (es) 2018-11-09

Family

ID=56285892

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017008939A MX2017008939A (es) 2015-01-06 2015-09-10 Forma de dosificacion que incluye una solucion solida de drogas amorfas.

Country Status (13)

Country Link
US (1) US20160193151A1 (es)
EP (1) EP3242650A4 (es)
JP (2) JP2018507180A (es)
KR (1) KR20180102484A (es)
BR (1) BR112017014675A2 (es)
CA (1) CA2973218A1 (es)
CO (1) CO2017006788A2 (es)
CR (1) CR20170361A (es)
DO (1) DOP2017000162A (es)
EC (1) ECSP17046608A (es)
MX (1) MX2017008939A (es)
PE (1) PE20171308A1 (es)
WO (1) WO2016111725A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2619840C1 (ru) * 2016-09-21 2017-05-18 Общество с ограниченной ответственностью "Изварино Фарма" Фармацевтическая композиция для лечения ВИЧ-инфекции
KR20180121352A (ko) * 2017-04-28 2018-11-07 닛토덴코 가부시키가이샤 경피 흡수형 제제
US20200405643A1 (en) * 2017-09-11 2020-12-31 Board Of Regents, The University Of Texas System Drug compositions containing porous carriers made by thermal or fusion-based processes
US20200206139A1 (en) * 2017-09-11 2020-07-02 Board Of Regents, The University Of Texas System Compositions for the improved delivery of drugs
MX2020005518A (es) 2017-12-05 2020-11-06 Sunovion Pharmaceuticals Inc Mezclas no racemicas y usos de las mismas.
JP2021505595A (ja) 2017-12-05 2021-02-18 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 結晶形およびその製造方法
WO2020072008A1 (en) * 2018-10-04 2020-04-09 Deva Holding Anonim Sirketi Novel solid dispersions of selinexor
JP2022535893A (ja) 2019-06-04 2022-08-10 サノビオン ファーマシューティカルズ インク 放出調節製剤およびその使用
CN110585156B (zh) * 2019-10-24 2021-09-28 中国人民解放军军事科学院军事医学研究院 一种对乙酰氨基酚缓释制剂及其3d打印制备方法
WO2021188517A1 (en) * 2020-03-17 2021-09-23 Rutgers, The State University Of New Jersey Continuous melt-coating of active pharmaceutical ingredients using surfactants for dissolution enhancement
AU2021248406A1 (en) * 2020-04-01 2022-10-13 Board Of Regents, The University Of Texas System Pharmaceutical compositions of niclosamide
KR102594715B1 (ko) * 2020-04-17 2023-10-27 영남대학교 산학협력단 경구 생체 이용률이 증가된 니클로사마이드 함유 고체분산체 및 이의 제조방법
EP4236953A1 (en) * 2020-10-27 2023-09-06 ISP Investments LLC Method and system for predicting properties of amorphous solid dispersions using machine learning
GB2607554B (en) * 2021-03-04 2024-04-10 Reckitt Benckiser Health Ltd Novel composition
AU2022240737A1 (en) * 2021-03-17 2023-09-28 Procaps Sa Pre-filling system to eliminate bubbles inside capsules having a solid dosage form
CN114073679A (zh) * 2021-10-13 2022-02-22 广州汇元医药科技有限公司 一种塞来昔布组合物及其制备方法和应用
WO2023145869A1 (ja) * 2022-01-31 2023-08-03 住友精化株式会社 製剤用組成物の製造方法及び製剤の製造方法
WO2023145871A1 (ja) * 2022-01-31 2023-08-03 住友精化株式会社 製剤用組成物の製造方法及び製剤の製造方法
WO2024092237A1 (en) * 2022-10-28 2024-05-02 Board Of Regents, The University Of Texas System Continuous mid-air 3-dimensional printing for pharmaceutical dosage forms

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU226586B1 (en) * 1998-12-16 2009-04-28 Aventis Pharma Inc Biodegradable polymer encapsulated serotonin receptor antagonist and method for preparing the same
CN101217981A (zh) * 2005-07-05 2008-07-09 阿伯特有限及两合公司 包含固体或半固体基质的组合物和剂型
WO2008037809A1 (en) * 2006-09-29 2008-04-03 Abbott Gmbh & Co. Kg Transmucosal administration of fibrate compounds and delivery system therefor
EP2429492B1 (de) * 2009-05-13 2014-06-25 Basf Se Feste pharmazeutische Zubereitungen enthaltend Copolymere auf Basis von Polyethern in Kombination mit wasserschwerlöslichen Polymeren
US20120202894A1 (en) * 2009-09-18 2012-08-09 Basf Se Rapidly Soluble Solid Pharmaceutical Preparations Containing Amphiphilic Copolymers Based On Polyethers In Combination With Hydrophilic Polymers
WO2011039675A2 (en) * 2009-09-30 2011-04-07 Pfizer Inc. Latrepirdine transdermal therapeutic dosage forms
EP2504033A1 (en) * 2009-11-24 2012-10-03 Basf Se Film-like pharmaceutical dosage forms
WO2011101352A2 (en) * 2010-02-18 2011-08-25 Abbott Gmbh & Co. Kg Test solvent for evaluating the compatibility of biologically active substances and graft copolymers
NZ605440A (en) * 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
RU2489445C2 (ru) * 2011-04-13 2013-08-10 Владимир Дмитриевич Артемьев Способ получения из топинамбура инулинсодержащего раствора, способ получения инулина и способ получения фруктоолигосахаридов на основе этого раствора

Also Published As

Publication number Publication date
WO2016111725A1 (en) 2016-07-14
ECSP17046608A (es) 2017-07-31
JP2021059540A (ja) 2021-04-15
EP3242650A4 (en) 2018-08-01
CR20170361A (es) 2018-01-25
KR20180102484A (ko) 2018-09-17
JP2018507180A (ja) 2018-03-15
CO2017006788A2 (es) 2017-07-19
DOP2017000162A (es) 2018-11-15
PE20171308A1 (es) 2017-09-05
BR112017014675A2 (pt) 2018-03-13
US20160193151A1 (en) 2016-07-07
CA2973218A1 (en) 2016-07-14
EP3242650A1 (en) 2017-11-15

Similar Documents

Publication Publication Date Title
MX2017008939A (es) Forma de dosificacion que incluye una solucion solida de drogas amorfas.
Elkhodairy et al. Formulation and optimization of orodispersible tablets of flutamide
MX2018002627A (es) Metodo de cristalizacion y biodisponibilidad.
MX356111B (es) Composiciones farmaceuticas disuasorias de abuso, de liberacion inmediata.
MX2020012310A (es) Formulaciones de liberacion prolongada de colchicina y metodos de uso de las mismas.
MX2018002462A (es) Una composicion farmaceutica para reducir la grasa localizada y sus usos.
EA201401348A1 (ru) Технология приготовления имплантируемой формы палиперидона
AR105203A1 (es) Formulación oral sólida que contiene irinotecán y método de preparación de la misma
PH12015502556A1 (en) Modified release formulation
NZ727834A (en) Fast acting orally disintegrating film
EA201691490A1 (ru) Фармацевтическая композиция, содержащая бринзоламид
PH12015501301A1 (en) A pharmaceutical composition containing candesartan cilexetil and amlodipine
BR112014032583A2 (pt) forma farmacêutica para liberação prolongada de substâncias ativas
WO2012147101A3 (en) Pharmaceutical compositions of raltegravir, methods of preparation and use thereof
BR112015010243A2 (pt) dispersão sólida, composição para administração oral, composição farmacêutica, e, método para preparar uma dispersão sólida
EA201691231A1 (ru) Фармацевтические лекарственные формы
EA201990129A1 (ru) Таблетированный состав с улучшенным профилем растворения для лечения болезни паркинсона
BR112017019364A2 (pt) dispersões sólidas
RU2016106328A (ru) Противотуберкулезная стабильная фармацевтическая композиция в форме диспергируемой таблетки, содержащей гранулированный изониазид и гранулированный рифапентин, и способ ее приготовления
IL281217A (en) Pharmaceutical preparation for controlled release of weak acid drugs and its uses
WO2011126327A3 (en) Pharmaceutical composition with controlled-release properties comprising mosapride or levodropropizine, and preparing method thereof
MX2016010191A (es) Composicion solida con un inhibidor de la cox 2.
WO2013054178A3 (en) Extended release pharmaceutical compositions containing carmabazepine
최종훈 et al. Sustained release of anti-tumor drug molecules from engineered self-expanding hydrogels
TR201103946A1 (tr) Kontrollü salım sağlayan gliklazid formülasyonları.